LCM
BOLT icon

Lynx1 Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

Lynx1 Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Hold
30,800
– – 0.01% 24
2026
Q1 		$124K Buy
+30,800
New +$160K 0.02% 20

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lynx1 Capital Management's BOLT Position: Q2 2026 in Review

Lynx1 Capital Management held its Bolt Biotherapeutics (BOLT) position steady in Q2 2026 at 30,800 shares worth $119K. The position accounts for 0.01% of the portfolio, ranked #24.

Lynx1 Capital Management first reported a position in BOLT in Q1 2026 and has held it in 2 quarters since. The position peaked at $124K in Q1 2026. 19 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Lynx1 Capital Management held 30,800 shares of Bolt Biotherapeutics worth $119K as of Q2 2026.
  • Lynx1 Capital Management left its Bolt Biotherapeutics share count unchanged in Q2 2026.
  • Bolt Biotherapeutics made up 0.01% of Lynx1 Capital Management's portfolio in Q2 2026, its #24 holding.
  • Lynx1 Capital Management first reported a position in Bolt Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • Lynx1 Capital Management's Bolt Biotherapeutics position peaked at $124K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.